Welcome to the second of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how digital differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In this second episode, we consider information governance and data privacy: when life science and technology companies decide to partner, they quickly discover that there is an inherent conflict between the demands of good information governance on the one hand, which requires control processes and regulatory compliance, and innovation on the other, which requires freedom. How should acquirers and targets manage the resulting frictions in navigating digital deals? Click below to listen. You can add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
If you want to listen to the first episode - Corporate Culture - please visit our Insights page. You can also learn more by downloading our report which accompanies this podcast series. 👇
Are you ready for a digital-first future in life sciences? This new report explores the challenges and opportunities presented by digital deals. Essential reading for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving artificial intelligence, machine learning and big data, our report provides insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. To receive a copy, please fill in your details in the form at the bottom of the page. 👇
